UPDATE : Friday, May 17, 2019
상단여백
Saxenda's sales surge 3,000 times yoy in Q1 by Lee Han-soo 2019-05-17 14:37
Daewoong launches Nabota in US amid controversy by Lee Han-soo 2019-05-16 16:33
Latecomer SGLT2 inhibitor Steglatro unlikely to get free ride by Kim Yun-mi 2019-05-15 15:30
Keytruda wins nod as adjuvant therapy after melanoma surgery by Kim Yun-mi 2019-05-15 14:14
EU lists Korea on drug standard whitelist by Lee Han-soo 2019-05-15 13:25
라인
J&J's nasal spray depression treatment still met with some skepticism by Lee Han-soo 2019-05-14 15:26
‘MSD Korea’s foreign exec got drunk, sexually harassed female worker’ by Jeong Sae-im 2019-05-14 11:53
Korean companies excel multinational pharma’s R&D in investment-sales ratio by Lee Han-soo 2019-05-13 17:27
Chinese patients vaccinate MSD’s product in Korea. Why? by Lee Han-soo 2019-05-13 14:57
US trade agency orders Daewoong to submit Nabota’s strain by Lee Han-soo 2019-05-13 14:37
라인
Antibody-drug conjugates on the rise as Herceptin’s patent to expire soon by Kim Yun-mi 2019-05-13 14:23
Pfizer keeps lead over multinational pharmas in 2018 sales by Lee Han-soo 2019-05-10 17:17
Xeljianz is easier to use than biologic therapies -- is it safer, however? by Kim Yun-mi 2019-05-10 15:34
[Exclusive] MSD Korea playing tricks to reduce daycare cost by Kim Yun-mi 2019-05-09 11:20
T&R Biofab, CiSTEM to co-develop rare disease treatments by Lee Han-soo 2019-05-09 11:17
라인
‘GC Wellbeing’s placenta injection has liver regenerative effects’ by Lee Han-soo 2019-05-08 17:07
Celgene’s myelodysplastic syndrome treatment gets more insurance benefits by Lee Han-soo 2019-05-07 17:36
GC Cell to start developing CAR-T treatment for pancreatic cancer by Lee Han-soo 2019-05-07 16:10
FDA OKs Gemvax & Kael's Alzheimer treatment for P2 trials by Lee Han-soo 2019-05-07 16:09
[Exclusive] MSD workers appalled by executive’s remarks on childcare leave by Jeong Sae-im 2019-05-07 12:08
여백
여백
여백
Back to Top